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Abstract: Stem cell-derived hepatocytes represent promising models to study human liver 
biology and disease. This concise review discusses the recent progresses in the field, with a 
focus on human liver disease, drug metabolism and virus infection. 
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1. Introduction 
The human liver has a multitude of functions. The cells which comprise the liver and perform those 
roles are termed parenchymal and non-parenchymal. Approximately 70%–80% of the liver is composed 
of the parenchymal cells known as hepatocytes. The non-parenchymal fraction make up the rest of the 
organ and are localized in the sinusoidal and biliary compartments of the tissue [1]. The hepatocyte 
compartment performs many metabolic and synthetic functions, for example storage and mobilization of 
sugars, maintenance of the blood clotting factors and the processing of drugs. Therefore, maintaining 
hepatic function is vital for normal physiology, and long-term damage to this compartment is 
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detrimental to human health. Liver disease can be caused by a number of different stimuli, such as viral 
infection, excess alcohol or the exposure to prescription or recreational drugs. In the normal setting, the 
hepatocyte is capable of organ regeneration and restoration of normal function. However, in the  
chronic injury setting the residential stem cell population is required to restore liver mass and ultimately  
function [2].  
Given the dire consequences of severe liver damage, a number of cell based models have been 
developed to predict the potential for human liver injury (for a review see [3]). Freshly isolated human 
primary hepatocytes (PHHs) are recognized as the “gold standard” for evaluating liver metabolism and 
drug toxicity [4]. PHHs express many of the essential drug metabolizing enzymes for several days in 
tissue culture following their isolation. However, enzyme expression drops off markedly during cell 
culture which can complicate biological interpretation [5,6]. In addition to their instability, PHHs 
widespread use is limited by their scarcity and quality [7]. 
To overcome the shortage and stability of PHHs, a number of different human hepatoma-derived cell 
lines have been established. In contrast to PHHs, hepatoma-derived cells are scalable, cheap to maintain 
and are easy to handle. However, those benefits are out-weighed by defects in key cell signaling 
pathways which result in inferior phenotype. For example, Huh7.5 cells are used to study Hepatitis C 
virus (HCV) replication but are not ideal to study virus-host interaction due to defects in the retinoic 
acid-inducible gene 1 pathway [8]. Additionally, hepatoma-derived cell lines display limited capacity 
for drug metabolism due to poor cytochrome P450 gene expression [9–11]. With the advent of 
pluripotent stem cell technology, it is now possible to produce stem cell-derived hepatocyes at scale and 
from known genetic background. We believe that this has revolutionary potential for modern medicine 
(Figure 1) and discuss the potential of stem cells in more detail throughout the review. 
Figure 1. Modeling human liver biology using stem cell-derived hepatocytes. Hepatocytes 
derived from pluripotent stem cells (embryonic stem cells and induced pluripotent stem 
(iPS) cells), adult stem cells, or somatic cells can be used for modeling human liver biology 
“in a dish”. Examples of the use of this technology include, toxicity screening, disease 
modeling, viral infection and replication. 
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2. Generation of In Vitro-Derived Hepatocytes from Stem Cell or Somatic Cells 
2.1. Hepatocytes Derived from Human Embryonic Stem Cells (hESCs) 
hESCs are derived from the inner cell mass of preimplantation embryos [12]. They have the ability to 
self-renew, and at the same time retain the ability to differentiate to all three germ layers [13]. Therefore, 
it is possible to scale large numbers of stem cells and their derivatives for downstream application [14]. 
hESCs have been differentiated into functional hepatic endoderm using spontaneous or directed 
differentiation [15–18]. During spontaneous differentiation, hESCs are maintained in suspension to 
induce differentiation into embryoid bodies (EBs) [19]. Those EBs are further stimulated to differentiate 
toward the hepatocyte lineage using physiological cues [20]. While the process is resilient, the efficiency 
of stem cell-derived hepatocytes generated using this method is low and requires further  
enrichment [16,21]. During directed differentiation, hESCs are differentiated to hepatocytes in adherent 
and 2 dimensional monolayer culture. Several groups have confirmed this method is possible and more 
efficient than spontaneous differentiation [17,22,23]. In both procedures, definitive endoderm is 
specified from hESCs and then induced to differentiate along the hepatic lineage by the sequential 
addition of inducing factors. We have developed a highly efficient method to deliver functional 
hepatocytes which could be assayed in a high throughput format [18]. Since those early discoveries, we 
and others have delivered scalable populations of stem cell-derived hepatocytes using serum-free and 
synthetic components [24,25]. Most recently, exciting studies by Vosough et al. demonstrated scalable 
suspension culture for stem cell expansion and differentiation. Most notably, pluripotent stem cells were 
expanded and differentiated toward the hepatocyte lineage at a scale that would satisfy liver cell-based 
therapy requirements [21,26]. 
2.2. Hepatocytes Derived from Induced Pluripotent Stem Cells (iPSCs) 
Differentiated somatic cells can be reprogrammed to an ES-like state [27] termed induced pluripotent 
stem cells (iPSCs). As with the hESCs, iPSCs theoretically offer a potential source of somatic cells in 
large numbers [28]. Of note, iPSCs have been induced toward the hepatocyte lineage using similar 
protocols that were developed in hESCs [29]. Interestingly and in agreement with studies using hESCs, 
there are significant variations in iPSC hepatic differentiation capacity [29]. iPSC clones derived from 
peripheral blood cells were found to be comparable to dermal fibroblasts from the same individual, but 
differentiation capacity varied from donor to donor using a modified version of our procedure [18,30]. 
2.3. Hepatocytes from Direct Reprogramming Somatic Cells 
Reprogramming of fibroblasts to iPSC demonstrated that somatic cells could be reprogrammed to a 
pluripotent stem cell state [31,32]. It has also been demonstrated that somatic cells are capable of 
trans-differentiation to heptocytes using specific sub sets of transcription factors. Murine somatic cells 
have been successfully reprogrammed to hepatocyte-like cells [33,34]. Hepatocytes were derived from 
mouse tail-tip fibroblasts and transduced with virus expressing Gata4, HNF1α and Foxa3 [30]. In these 
studies there was a requirement for the inactivation of p19 (Arf) [33]. In a separate study, mouse 
embryonic and adult fibroblasts were trans-differentiated using combinations of HNF4α plus Foxa1, 
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Foxa2 or Foxa3 [34]. Importantly, the derivative hepatocytes exhibited similar function to primary 
hepatocytes. Encouragingly, trans-differentiated heaptocytes were transplanted in vivo and repopulated 
the livers of fumarylacetoacetate-hydrolase-deficient mice, rescuing almost half of recipients [33]. Most 
recently, the transcription factor cocktail was modified to HNF1β and Foxa3, which yielded a cell type 
reminiscent of bipotent hepatic stem cells [35]. Until now, the direct reprogramming to hepatocytes has 
not been accomplished in human cells, but this cannot be far off. In support of this, over expression of 
lineage-specific transcription factors has been shown to directly convert terminally differentiated cells 
into other lineages, including neurons, cardiomyocytes and blood progenitors [36–38]. 
3. Modeling Human Drug Metabolism Using Stem Cell-Derived Hepatocytes 
3.1. Drug Attrition  
The drug discovery process is a rocky road and pharmaceutical companies face major issues with 
drug attrition [39]. It is estimated that the average cost to bring a new drug to market ranges between 
$800 million and $2 billion [40]. Issues associated with cardiac and liver toxicity, among others, are a 
major concern during this process [41]. Therefore, human models, which accurately reflect physiology, 
could impact on the spiraling costs associated with drug development. As previously detailed, PHHs 
represent the “gold standard” [42], but their limited availability and stability restricts widespread use.  
A credible alternative for the future, are pluripotent stem cell-derived hepatocytes, which have already 
shown great potential in the determination of human drug metabolism and hepatotoxicity [43].  
3.2. Stem Cell-Derived Hepatocytes 
Drug metabolism in the liver can be divided into three phases. Phase I reactions are carried out by the 
cytochrome P450 enzymes (CYPs) which modify the chemical substrate via oxidation, reduction and/or 
hydrolysis. CYPs are the major enzymes involved in drug metabolism [44]. The major CYP enzymes 
involved in drug metabolism include; the CYP1A family, CYP2A6, CYP2B6, the CYP2C family, 
CYP2D6, CYP2E1, and the CYP3A family [45]. Among them, CYP3A4 is the most abundant isoform 
in human liver and has been estimated to be involved in the metabolism of approximately 50% of 
prescribed medicines [46]. Phase II reactions are conjugation reactions which modify drug and 
metabolite polarity, rendering the products more water soluble. Following this, the Phase III reactions 
are responsible for metabolite transport across the cell membrane. In this stage, transporters, such as 
multi-drug resistance-associated protein 2 and permeability glycoprotein, move metabolites across the 
cell barriers in an energy dependent process [47]. Phase I–III reactions are vital to normal hepatocyte 
function. Unfortunately, drug metabolism, conjugation and transport decrease with time in cell culture 
and has been attributed to sub-optimal tissue culture microenvironments [48]. Recently, our laboratory 
identified a synthetic polymer which delivers phenotypically stable hepatocyte populations for at least 
15 days, in two dimensional and three-dimensional format. Importantly, the stem cell derived 
heaptocytes replated on this material displayed equivalence to the current gold standard demanded by 
regulatory authorities [25,43]. In addition to our approach, other groups have also studied human liver 
toxicity using stem cell derived hepatocytes. In a recent study by Yildirimman et al., stem cell-derived 
hepatocytes were exposed to numerous agents classified as noncarcinogens, genotoxic carcinogens, and 
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nongenotoxic carcinogens [49]. Changes in hepatic transcriptome were analyzed using gene expression 
microarrays. Encouragingly, stem cell-derived hepatocytes correlated well with that of PHHs. 
4. Modeling Human Disease Using Stem Cell-Derived Hepatocytes 
4.1. Modeling Human Genetic Liver Disorders  
Stem cell-derived hepatocytes generated from patients with metabolic liver diseases are a  
useful model for understanding the disease process. Various human inherited liver diseases  
such as: a1-antitrypsin deficiency; Glucose-6-phosphate deficiency; LDL-receptor mutations; 
Crigler-Najjar-Syndrome; and Wilson’s disease have been successfully modeled “in a dish” using 
iPS-derived hepatocytes from the patients [50–52]. In addition to understanding disease better, these 
models also provide useful platforms to screen for new drugs to better treat disease and therefore 
represent exciting advances. 
4.2. Hepatitis Virus Infection and Replication 
In addition to modeling inherited liver diseases, stem cell-derived hepatocytes have proved useful in 
delivering models for studying the lifecycle of hepatotropic viruses. This is very important as current 
approaches using human hepatoma cell culture to model hepatitis C virus (HCV) lifecycle has a number 
of drawbacks and as a result does not support the growth of clinical viral isolates. This precludes studies 
of many important host-pathogen interactions that are crucial for a more detailed understanding of viral 
life cycle and pathogenesis. This has necessitated the development of models which are phenotypically 
closer to human hepatocytes. Encouragingly, stem cell-derived hepatocytes have been shown to support 
the entire life cycle of the HCV including viral entry, replication, production and release of progeny 
virus, albeit at low levels [53–55]. However, there are still few reports on applying stem cell-derived 
hepatocytes to other hepatotropic viruses including hepatitis B virus (HBV) and hepatitis D virus (HDV) 
which affect more than 2 billion people worldwide [56–58]. A suitable model for HBV, and the 
associated, HDV are needed to provide key clues to viral lifecycle and pathogenesis. Of note, sodium 
taurocholate, a transport polypeptide, was recently discovered as a new functional receptor of HBV and 
HDV [59] and represents substantial progress in this field. We believe that stem cell-derived hepatocytes 
offer promising models for HBV and HDV studies. 
Another important goal of developing such virus models, is to further our understanding of the affect 
that genetic background has on viral pathogenesis. Certain individuals are prone to developing chronic 
viral infection while others can efficiently clear the virus. A reasonable explanation may lie in 
differences in immune factors or viral receptor expression. However, the true reasons for these different 
responses are still largely unresloved. We believe that stem cell derived models, from defined genetic 
origin, may provide insight into the disease process and currently available treatments. In the future, 
such models could facilitate the development of new anti-viral drugs, which can be tailored to the 
patient’s genetics.  
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4.3. Alcoholic Liver Disease 
Liver disease, such as fatty liver, cirrhosis, and hepatocellular carcinoma are closely associated with 
alcohol abuse [60]. To investigate the mechanisms by which alcohol affects liver biology, many 
laboratories have used animal models, histology, primary human hepatocytes and hepatoma cell  
lines [61]. However, these models do not accurately reflect the situation within human liver as alcoholic 
liver disease pre-disposition is largely dependent on the individual’s genetics.  
Human hepatocytes, are the major cell type in the liver which undertakes alcohol metabolism. 
Hepatocytes degrade alcohol into aldehyde by alcohol dehydrogenase and catalyze the oxidation of 
aldehydes to carboxylic acids by aldehyde dehydrogenase. In addition to tissue damage, alcohol and its 
metabolites, can trigger the innate immune response, contributing to inflammation [3,62]. Most recently, 
stem cell derived heaptocytes have been shown to have an important role to play in modeling human 
hepatocyte response to alcohol. Alcohol was found to induce apoptosis and disturb stem cell-derived 
hepatocyte differentiation as well as impair the survival and proliferation of stem cell-derived 
hepatocytes [63]. This has raised the possibility that by applying stem cell-derived hepatocytes from 
defined genetic origin, in a context of ALD, will allow the more detailed analysis of an individual’s 
response to alcohol metabolism and disease progression.  
5. Challenge and Prospect of Stem Cell-Derived Hepatocytes 
Many methods have been devised to efficiently generate stem cell-derived hepatocytes from hESCs 
or hiPSCs (for a review see Szkolnicka et al. 2013 [64]). There are still challenges to be faced when 
using stem cell-derived hepatocytes to model human liver physiology. Those challenges include, bona 
fide differentiation, cost effective scale up and reliable and stable performance. That being said, mature 
cell populations are emerging which deliver reliable biological readouts and represent exciting advances 
in the field, likely to impact on modern medicine [65]. 
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